| Sponsor |
Protocol Code |
Trial Name |
Principal Investigator |
Phase |
Therapeutic Area |
Diseases and Conditions |
| Lilly |
I8F-MC-GPGN |
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT) |
OĞUZHAN DEYNELİ (Prof.Dr.) |
Phase 2b |
Endocrinology, Diabetes and Metabolic Diseases |
Diabetes Mellitus |
| Boehringer Ingelheim |
1404-0040 |
A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study with BI 456906 Administered Subcutaneously Compared with Placebo in Participants with Overweight or Obesity with Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD |
DİLEK YAZICI (Prof.Dr.) |
Phase 3 |
Endocrinology, Diabetes and Metabolic Diseases |
Obesity and Cardiovascular Diseases |
| Syneos Health |
IMVT-1401-3202 |
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) |
OĞUZHAN DEYNELİ (Prof.Dr.) |
Phase 3 |
Endocrinology, Diabetes and Metabolic Diseases |
Thyroid |
| Roche |
DC000129 |
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range of 70-180 mg/dL Compared to SMBG |
OĞUZHAN DEYNELİ (Prof.Dr.) |
Medical Device |
Endocrinology, Diabetes and Metabolic Diseases |
Diabetes Mellitus |
| AMGEN |
20220196 |
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) |
DİLEK YAZICI (Prof.Dr.) |
Phase 3 |
Endocrinology, Diabetes and Metabolic Diseases |
Obesity and Cardiovascular Diseases |
| ROCHE |
WC45726 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants with Obesity or Overweight and Type 2 Diabetes |
DİLEK YAZICI (Prof.Dr.) |
Phase 3 |
Endocrinology, Diabetes and Metabolic Diseases |
Diabetes Mellitus and Obesity |